Evidence map›Paper›PMID 40410902›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

Characterization of extracellular vesicle-associated DNA and proteins derived from organotropic metastatic breast cancer cells.

Amélie Nadeau, Thupten Tsering, Mohamed Abdouh, Laura Kienzle, Jenna Cleyle, Lorne Taylor, Noélie Douanne, Kyle Dickinson, Peter M Siegel, Julia V Burnier

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Extracellular vesicles as modulators of cancer metabolism and microenvironment.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amélie NadeauCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Thupten TseringCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Mohamed AbdouhCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Laura KienzleCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jenna CleyleCentre for Translational Biology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Lorne TaylorCentre for Translational Biology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Noélie DouanneCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Kyle DickinsonCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Peter M SiegelRosalind & Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.
Julia V BurnierCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. julia.burnier@mcgill.ca.

Funding

Fonds de Recherche du Québec - Santé 312831 344929
6 · The paper itself

Abstract

backgroundWhile primary breast cancer (BC) is often effectively managed, metastasis remains the primary cause of BC-related fatalities. Gaps remain in our understanding of the mechanisms regulating cancer cell organotropism with predilection to specific organs. Unraveling mediators of site-specific metastasis could enhance early detection and enable more tailored interventions. Liquid biopsy represents an innovative approach in cancer involving the analysis of biological materials such as circulating tumor DNA and tumor-derived extracellular vesicles (EV) found in body fluids like blood or urine. This offers valuable insights for characterizing and monitoring tumor genomes to advance personalized medicine in metastatic cancers.

methodsWe performed in-depth analyses of EV cargo associated with BC metastasis using eight murine cell line models with distinct metastatic potentials and organotropism to the lung, the bone, the liver, and the brain. We characterized the secretome of these cells to identify unique biomarkers specific to metastatic sites.

resultsSmall EVs isolated from all cell lines were quantified and validated for established EV markers. Tracking analysis and electron microscopy revealed EV secretion patterns that differed according to cell line. Cell-free (cf)DNA and EV-associated DNA (EV-DNA) were detected from all cell lines with varying concentrations. We detected a TP53 mutation in both EV-DNA and cfDNA. Mass spectrometry-based proteomics analyses identified 698 EV-associated proteins, which clustered according to metastatic site. This analysis highlighted both common EV signatures and proteins involved in cancer progression and organotropism unique to metastatic cell lines. Among these, 327 significantly differentially enriched proteins were quantified with high confidence levels across BC and metastatic BC cells. We found enrichment of specific integrin receptors in metastatic cancer EVs compared to EVs secreted from non-transformed epithelial cells and matched tumorigenic non-metastatic cells. Pathway analyses revealed that EVs derived from parental cancer cells display a cell adhesion signature and are enriched with proteins involved in cancer signaling pathways.

conclusionTaken together, the characterization of EV cargo in a unique model of BC organotropism demonstrated that EV-DNA and EV proteomes were informative of normal and cancer states. This work could help to identify BC biomarkers associated with site-specific metastasis and new therapeutic targets.

Indexed as

Breast NeoplasmsExtracellular VesiclesAnimalsBiomarkers, TumorCell Line, TumorFemaleHumansMiceNeoplasm MetastasisBiomarkers, TumorBiomarkersDNAExtracellular vesiclesMetastatic breast cancerOrganotropismProteomics

Identifiers

PMID40410902
PMCPMC12100931

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.